Stroke risk in women: the role of menopause and hormone therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22172623.
- Also identified by DOI 10.1016/S1474-4422(11)70269-1 and PMC identifier 3615462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although women have a lower risk of stroke during middle age than men, the menopausal transition is a time when many women develop cardiovascular risk factors. Additionally, during the 10 years after menopause, the risk of stroke roughly doubles in women. Endogenous oestrogen concentrations decline by 60% during the menopausal transition, leading to a relative androgen excess, which could contribute to the increased cardiovascular risk factors in women. Earlier onset of menopause might affect the risk of stroke, but the data are not clear. Because of the stroke risk associated with it, hormone therapy is recommended only for treatment of vasomotor symptoms, and some formulations might be safer than others. More research is needed to understand which women are at greatest stroke risk during midlife and to identify the safest formulation, dose, and duration of hormone therapy that can be used to treat vasomotor symptoms without increasing the risk of stroke.
Medical subject headings
- Estrogen Replacement Therapy
- Menopause
- Stroke
- Women's Health